Loading...
Market
What will be the market share of WINREVAIR™ in the PAH treatment market in Europe by December 31, 2024?
2
Resolution / Starting Odds
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Market analysis reports from industry analysts or Merck's financial reports
Story
Merck's WINREVAIR™ Gains EU Approval for PAH Treatment
Aug 26, 2024, 06:41 AM
Merck has received approval from the European Commission for WINREVAIR™ (sotatercept) in combination with other therapies for the treatment of pulmonary arterial hypertension (PAH) in adult patients with functional class II-III. This approval marks a significant advancement in the treatment options available for PAH, a condition characterized by high blood pressure in the arteries of the lungs, which can lead to heart failure if untreated. The approval of WINREVAIR™ is expected to enhance the therapeutic landscape for PAH patients in Europe.
View original story
Similar markets
Less than 5% • 25%
5% to 10% • 25%
10% to 15% • 25%
More than 15% • 25%
Less than 10% • 25%
10% - 20% • 25%
20% - 30% • 25%
More than 30% • 25%
Top 3 • 25%
Top 5 • 25%
Top 10 • 25%
Below Top 10 • 25%
Less than 10% • 25%
10% to 30% • 25%
30% to 50% • 25%
More than 50% • 25%
European Union • 25%
Japan • 25%
Canada • 25%
Other • 25%
<10% • 25%
10-25% • 25%
25-50% • 25%
>50% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%